Growth hormone replacement and the risk of malignancy in children with neurofibromatosis.
AffiliationDepartment of Endocrinology, Christie Hospital NHS Trust, Withington, Manchester, United Kingdom.
MetadataShow full item record
AbstractOBJECTIVE: To assess the efficacy and safety of growth hormone (GH) therapy in children with GH deficiency in association with neurofibromatosis. METHODS: Retrospective analysis of data from the Pharmacia and Upjohn International Growth Database (KIGS) in a total of 102 GH-deficient children with neurofibromatosis treated with recombinant GH. RESULTS: Median pretreatment height velocity was 4.2 cm/yr (1.7 to 6.4 cm/yr), increased to 7.1 cm/yr (4.6 to 10.0 cm/yr) in the first year of GH therapy, and remained significantly greater than pretreatment at 5.7 cm/yr (2.9 to 8.3 cm/yr) and 5.7 cm/yr (2.6 to 7.9 cm/yr) in the second and third years, respectively. The median height SD score increased from -2.4 to -1.8 by the end of 3 years of treatment. Five patients had either a recurrence of an intracranial tumor or a second intracranial tumor; this incidence of tumor occurrence is comparable to that reported previously in similar patients with neurofibromatosis. Other adverse events were relatively minor and unlikely to be attributable to GH therapy CONCLUSIONS: The data indicate that GH replacement therapy, per se, for patients with neurofibromatosis and GH deficiency is likely to be beneficial and unassociated with excessive malignant risk.
CitationGrowth hormone replacement and the risk of malignancy in children with neurofibromatosis. 1998, 133 (2):201-5 J. Pediatr.
JournalJournal of Pediatrics
- Derivation and validation of a mathematical model for predicting the response to exogenous recombinant human growth hormone (GH) in prepubertal children with idiopathic GH deficiency. KIGS International Board. Kabi Pharmacia International Growth Study.
- Authors: Ranke MB, Lindberg A, Chatelain P, Wilton P, Cutfield W, Albertsson-Wikland K, Price DA
- Issue date: 1999 Apr
- Height prognosis of children with true precocious puberty and growth hormone deficiency: effect of combination therapy with gonadotropin releasing hormone agonist and growth hormone.
- Authors: Cara JF, Kreiter ML, Rosenfield RL
- Issue date: 1992 May
- Efficacy and safety of growth hormone treatment in children with prior craniopharyngioma: an analysis of the Pharmacia and Upjohn International Growth Database (KIGS) from 1988 to 1996.
- Authors: Price DA, Wilton P, Jönsson P, Albertsson-Wikland K, Chatelain P, Cutfield W, Ranke MB
- Issue date: 1998
- Increased response, but lower responsiveness, to growth hormone (GH) in very young children (aged 0-3 years) with idiopathic GH Deficiency: analysis of data from KIGS.
- Authors: Ranke MB, Lindberg A, Albertsson-Wikland K, Wilton P, Price DA, Reiter EO
- Issue date: 2005 Apr
- The response to treatment with pituitary growth hormone: the New Zealand experience.
- Authors: Livesey JH, Cuneo RC, Donald RA, Harris RG, Ibberston HK, Costello JM, Holdaway IM, Gluckman PD, Fraser TR, Chapman GE
- Issue date: 1989 Aug 9